GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
The DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Serum calcitonin (CT) is a well-accepted marker of C-cell proliferation, particularly in medullary thyroid carcinoma. Chronic glucagon-like peptide-1 (GLP-1) receptor agonist administration in rodents has been associated with increased serum CT levels and C-cell tumor formation. There are no longitudinal studies measuring CT in humans without medullary thyroid carcinoma or a family history of medullary thyroid carcinoma and no published studies on the effect of GLP-1 receptor agonists on human serum CT concentrations. AIM: The aim of the study was to determine serum CT response over time to the GLP-1 receptor agonist liraglutide in subjects with type 2 diabetes mellitus or nondiabetic obese subjects. METHODS: Unstimulated serum CT concentrations were measured at 3-month intervals for no more than 2 yr in a series of trials in over 5000 subjects receiving liraglutide or control therapy. RESULTS: Basal mean CT concentrations were at the low end of normal range in all treatment groups and remained low throughout the trials. At 2 yr, estimated geometric mean values were no greater than 1.0 ng/liter, well below upper normal ranges for males and females. Proportions of subjects whose CT levels increased above a clinically relevant cutoff of 20 ng/liter were very low in all groups. There was no consistent dose or time-dependent relationship and no consistent difference between treatment groups. CONCLUSIONS: These data do not support an effect of GLP-1 receptor activation on serum CT levels in humans and suggest that findings previously reported in rodents may not apply to humans. However, the long-term consequences of GLP-1 receptor agonist treatment are a subject of further studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [76]
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Self-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Self-citationZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Self-citationMarre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Self-citationBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Self-citationPratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Cited by
Items 101–192 of 192
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Montanya, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.692777 · Cited by 27
“Calcitonin concentrations were monitored in > 5000 T2D or obese nondiabetic patients from nine clinical trials of liraglutide, and no significant differences were observed between liraglutide-treated and comparator-treated patients [84].”
BackgroundInterpreting Adverse Signals in Diabetes Drug Development Programs
Bailey, C. J. (2013) · Diabetes Care · doi:10.2337/dc13-0182 · Cited by 31
“In clinical studies, liraglutide slightly raised calcitonin concentrations, but human thyroid C cells have a low expression of GLP-1 receptors, and calcitonin concentrations were not elevated to an extent that is considered a signal for medullary C-cell cancer (66).”
BackgroundGLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells
Zhang, X., Zhang, L., Wang, B., Zhang, X., Gu, L., Guo, K., Zhang, X., & Zhou, Z. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.14.37 · Cited by 34
“Although calcitonin is a critical biomar - ker for MTC existence (13, 18, 19), it was not found that GLP-1RAs mediates elevation of calcitonin in non-human primates (17, 18) or patients with type 2 diabetes (20, 21).”
BackgroundLiraglutide for the Treatment of Type 2 Diabetes: A Clinical Update
Peters, K. R. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182204c16 · Cited by 25
“However, a recent study reported that GLP-1 receptor activation via liraglutide among healthy people and those with T2DM had no effect on serum calcitonin (CT), a well-accepted marker of C-cell proliferation, suggesting that the findings previously reported in rodents may not apply to humans.(48)”
BackgroundGut hormones and bone homeostasis: potential therapeutic implications
Bouvard, B., & Mabilleau, G. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01000-z · Cited by 29
“the acute effects of GLP1 on circulating levels of CTX in humans 44,50 cannot be explained by a direct stimulation of calcitonin release 93 .”
Guastamacchia, E., Triggiani, V., Aglialoro, A., Aiello, A., Ianni, L., Maccario, M., Zini, M., Giorda, C. B., Guglielmi, R., Betterle, C., et al. (2014) · Endocrine · doi:10.1007/s12020-014-0474-9 · Cited by 25
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Liraglutide in the treatment of obesity
Ng, S. Y. A., & Wilding, J. P. H. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.925870 · Cited by 27
“Calcitonin is released from C-cells in rodents following GLP-1 receptor activation but this was not observed in human C-cells [30,45].”
BackgroundThe role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
The Vitamin D Receptor in Thyroid Development and Function
Clinckspoor, I., Gérard, A.-C., SANDE, J. V., Many, M., Verlinden, L., Bouillon, R., Carmeliet, G., Mathieu, C., Verstuyf, A., & Decallonne, B. (2012) · European Thyroid Journal · doi:10.1159/000342363 · Cited by 22
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Beyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus
Goldman, J. D. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.44s · Cited by 23
Valentine, W. J., Palmer, A. J., Lammert, M., Langer, J., & Brändle, M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.022 · Cited by 20
Adverse Effects Associated With Newer Diabetes Therapies: A Review Article
Akiyode, O., & Adesoye, A. A. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190015594732 · Cited by 23
Gigoux, V., & Fourmy, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00050 · Cited by 21
Advances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L. M., Smits, M. M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 20
“Also, in over 5000 human subjects treated with liraglutide, plasma calcitonin levels remained low [97].”
BackgroundSafety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 30
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
“Also, in their clinical studies involving over 5000 individuals with type 2 diabetes or obese individuals without diabetes, Hegedus et al. (2011) showed that with liraglutide and exenatide use over 2 years, calcitonin levels gradually increased over time but without clinical significance [76].”
Pozo, L., Bello, F. O., Suárez, A., Ochoa-Martinez, F. E., Mendez, Y. H., Chang, C., & Surani, S. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.291 · Cited by 20
Madsbad, S. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.11.003 · Cited by 20
“Focus has been on whether incretin-based therapies can induce pancreatitis and medullary thyroid cancer in humans [63–69].”
BackgroundDefining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
“However, large-scale monitoring during clinical studies has not identified any indicators of cancer development, and no increased incidence of Ccell cancer was identified during the clinical studies of other GLP-1 RAs [76].”
BackgroundEffects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys
Vahle, J. L., Byrd, R. A., Blackbourne, J. L., Martin, J. A., Sorden, S. D., Ryan, T., Pienkowski, T., Wijsman, J. A., Smith, H. W., & Rosol, T. J. (2015) · Endocrinology · doi:10.1210/en.2014-1717 · Cited by 16
“In two separate human clinical trials of different GLP-1 receptor agonists, 2 years of liraglutide treatment and 2 years of dulaglutide treatment did not significantly increase calcitonin secretion, and overall mean serum calcitonin concentrations remained at the lower end of the normal range (30, 31).”
BackgroundLixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
Cao, Y., & Liu, X.-M. (2014) · Endocrine · doi:10.1007/s12020-014-0354-3 · Cited by 14
Diabetes and Cancer: Epidemiological, Clinical, and Experimental Perspectives
Tseng, C., Chen, C., & Landolph, J. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/101802 · Cited by 14
Chakraborty, S., Rendón-Ramírez, A., Ásgeirsson, B., Dutta, M., Ghosh, A. S., Oda, M., Venkatramani, R., Rao, B. J., Dandekar, A. M., & Goñi, F. M. (2013) · F1000Research · doi:10.12688/f1000research.2-286.v1 · Cited by 13
Clinical comments related to medullary thyroid cancer diagnosis and management
Duntas, L. H. (2013) · Thyroid Research · doi:10.1186/1756-6614-6-s1-s6 · Cited by 11
“Recently, a study was designed to determine whether GLP-1 receptor activation by liraglutide over a period of two years has an impact on Ct levels in type 2 diabetes mellitus and nondiabetes obese controls [16].”
BackgroundGLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 14
“reported that the GLP-1 receptor agonist liraglutide did not increase CT concentration after 2 years of treatment of over 5000 subjects [36].”
BackgroundSherman, S. I., Kloos, R. T., Tuttle, R. M., Pontecorvi, A., Völzke, H., Harper, K. D., Vance, C., Alston, J. T., Usborne, A. L., Sloop, K. W., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13437 · Cited by 15
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Garber, A. J. (2011) · PubMed · Cited by 11
Peterson, G. M. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.653392 · Cited by 11
STOLAR, M. W., Chen, S., & Grimm, M. F. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48837 · Cited by 12
“In humans, however, GLP-1RA use did not substantially raise calcitonin levels, and an analysis of sequential changes in calcitonin levels in several thousand diabetic subjects did not reveal a relationship between liraglutide therapy and plasma calcitonin.(50,51) In the meta-analysis described above on 3,261 EBID user…”
Safety of Anti-Obesity Drugs Approved for Long-Term Use
Kim, K. K. (2015) · The Korean Journal of Obesity · doi:10.7570/kjo.2015.24.1.17 · Cited by 10
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 12
“of GLP-1 receptors compared to rodents, and the GLP-1RAs do not cause a stimulated release of calcitonin [86,88].”
BackgroundLunati, M. E., Grancini, V., Colombo, C., Palmieri, E., Resi, V., Perrino, M., Orsi, E., & Fugazzola, L. (2015) · Metabolism · doi:10.1016/j.metabol.2015.09.010 · Cited by 12
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Emerging role of insulin with incretin therapies for management of type 2 diabetes
Ahluwalia, R., & Vora, J. P. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0005-0 · Cited by 10
Camacho, C. P., Lindsey, S. C., Kasamatsu, T. S., et al. (2014) · European Thyroid Journal · doi:10.1159/000363055 · Cited by 9
Treatment evaluation of liraglutide in type 2 diabetes
Kela, R., & Davies, M. J. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.716823 · Cited by 7
“Serum calcitonin, a bio-marker of thyroid C-cell hyperplasia and medullary thyroid cancer (MTC) was monitored in liraglutide-treated patients and remained in lower end of the normal range f over 2 years of follow-up [21].”
BackgroundA systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
“In addition, of the 5000 patients treated with liraglutide in clinical trials, none developed C-cell cancer and all studies, including long-term 2-year data, showed no increase in calcitonin levels compared to any active comparators [188].”
BackgroundTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 10
Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?
Gallo, M., Monami, M., Ragni, A., & Renzelli, V. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110624 · Cited by 7
Vahle, J. L., Dybowski, J., Graziano, M. J., Hisada, S., Lebron, J., Nolte, T., Steigerwalt, R. W., Tsubota, K., & Sistare, F. D. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1377990 · Cited by 7
New avenues for the pharmacological management of type 2 diabetes: An update
Cuny, T., Guerci, B., & Cariou, B. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.09.002 · Cited by 7
Kannan, S., & Nasr, C. E. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13066 · Cited by 8
“11 In a retrospective Adverse Event Reporting System database review, the incidence rate of thyroid cancer in patients treated with exenatide was higher—with an odds ratio of 4.7 (30 events)—than with a panel of control drugs (3 events).”
InfluentialDiabetes therapy and cancer risk: Where do we stand when treating patients?
Sun, G. E. C., Kashyap, S. R., & Nasr, C. E. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13140 · Cited by 6
Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 9
“Clinical trials have yielded inconclusive results regarding the increased risk [98].”
Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Bloomgarden, Z. T., Blonde, L., Garber, A. J., & Wysham, C. (2012) · Endocrine Practice · doi:10.4158/ep12300.ra · Cited by 8
Chakraborty, S., Rendón-Ramírez, A., Ásgeirsson, B., Dutta, M., Ghosh, A. S., Oda, M., Venkatramani, R., Rao, B. J., Dandekar, A. M., & Goñi, F. M. (2015) · F1000Research · doi:10.12688/f1000research.2-286.v3 · Cited by 8
Tierney, K. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00720.x · Cited by 6
“As with any new drug class, the long-term effects of GLP-1 receptor agonist treatment in humans will require further investigation (Hegedüs et al., 2011).”
BackgroundNonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4
“133,134 Human studies have not shown any increased risk of C cell hyperplasia or medullary thyroid carcinoma.”
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence
Tuccori, M., Convertino, I., Galiulo, M. T., Marino, A., Capogrosso-Sansone, A., & Blandizzi, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361401 · Cited by 5
Koller, D., Wendt, F., Pathak, G., Lillo, A. D., Angelis, F. D., Cabrera-Mendoza, B., Tucci, S., & Polimanti, R. (2021) · bioRxiv · doi:10.1101/2021.08.12.456138 · Cited by 4
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
Los nuevos antidiabéticos en el punto de mira… ¿razones de seguridad o caza de brujas?
Nicolau, J., & Masmiquel, L. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.11.002 · Cited by 4
Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence
Gale, S. E., Poon, J. L., & Watson, K. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2128 · Cited by 3
The new antidiabetic agents in the firing line… safety reasons or witch hunt?
Nicolau, J., & Masmiquel, L. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2011.11.003 · Cited by 7
Rosol, T. J., Braendli-Baiocco, A., Hoenerhoff, M. J., & Vahle, J. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-821046-8.00002-5 · Cited by 9
Agonistas del receptor de GLP-1
Huamán, H. C. A. (2020) · Diagnóstico · doi:10.33734/diagnostico.v59i2.219 · Cited by 4
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00042-5 · Cited by 4
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2
GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity
Palani, A., Zhou, Y., Halleck, M. M., & Carrington, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13765-5 · Cited by 3
Estimation of serum calcitonin, phosphate, and calcium in type 2 diabetes mellitus
Taher, Z. M., & Ahmed, S. (2023) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2023.023 · Cited by 2
Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide
Koro, C. E., Pientka, J., Bainbridge, V., O’Donnell, N., Stender, M., & Stemhagen, A. (2017) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0128-3 · Cited by 2
Barbato, G. M., Cadamuro, M., & Fabris, L. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.01.009 · Cited by 3
Incretin based therapies: Do they hold their promise?
Holst, J. J. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00186.x · Cited by 1
New and Future Medications for the Treatment of Type 2 Diabetes Mellitus
Mathers, M. C., Zarbock, S. D., & Sutton, E. E. (2014) · American Journal of Lifestyle Medicine · doi:10.1177/1559827613498694 · Cited by 2
“Until the risk has been clarified, once-weekly exenatide should not be used in patients with medullary thyroid carcinoma or hereditary C-cell hyperplasia or in individuals with first-degree family members who have these diseases because of the hereditary risk associated with them.(8,30) For this reason, the FDA has is…”
BackgroundAhluwalia, R., & Vora, J. P. (2012) · The British Journal of Diabetes · doi:10.1177/1474651411431846 · Cited by 1
Glucagon-like peptide-1 based therapies: Effects beyond blood glucose control
Sivaraman, S., Barber, T. M., O'Hare, P. J., & Randeva, H. S. (2013) · The British Journal of Diabetes · doi:10.1177/1474651413504119 · Cited by 1
Liraglutide in obesity: a guide to its use in the EU
Scott, L. J. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0241-x · Cited by 1
Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
Araújo, L. M. D. M., Feguri, S., de Oliveira, T. L., Pedrosa, F. B., Guimarães, R. G., de Sá, L. B. P. C., Rocha, D. R. T. W., & Arbex, A. K. (2016) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2016.61007 · Cited by 2
“These cases are not sufficient to establish or to deny a causal association [70] [71].”
BackgroundGiri, B., Sarkar, M., & Dey, S. (2017) · Journal of Stem Cell and Regenerative Biology · doi:10.15436/2471-0598.16.017 · Cited by 1
Zou, S., McDow, A. D., Saeed, Z. I., & Hou, T. (2023) · Cureus · doi:10.7759/cureus.33384 · Cited by 2
“Although most literature has shown that long-term use of GLP-1 Ra in humans has no effect on serum calcitonin level and do not cause C-cell-derived neoplasm [7], some recent data analysis reveals increased risk for thyroid cancer in patients receiving GLP-1 Ra treatment for T2DM [8].”
BackgroundLubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Management of Type 2 diabetes with liraglutide
Bohl, M., Overgaard, A., Pietraszek, A., & Hermansen, K. (2014) · Diabetes Management · doi:10.2217/dmt.13.72 · Cited by 1
and, C. R., & Petrie, J. R. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch6 · Cited by 1
Incretin-Based Treatment Strategy - GLP-1 Receptor Agonists (GLP-1R) or So-Called Incretin Mimetics
Perušičová, J., & Owe, K. (2011) · InTech eBooks · doi:10.5772/21873
LaSalle, J. R. (2013) · Osteopathic Family Physician · doi:10.1016/j.osfp.2012.11.002
“There are vast species differences in thyroid responses to GLP-1 RAs, with rodents having high expression of these receptors in C-cells, compared to monkeys or humans.(56,63) No specific laboratory monitoring is recommended.”
BackgroundGLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., & Costi, B. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_30
Bohl, M., Overgaard, A., Pietraszek, A., & Hermansen, K. (2014)
Krajewska, J., Krajewski, W. R., & Zatoński, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_59
Zoltán, K. I., Kun, I., & Kolcsár, M. (2019) · Orvostudományi Értesítö · doi:10.2478/orvtudert-2019-0016 · Cited by 1
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
Wojciechowska, J. K., Krajewski, W. R., Zatoński, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_63
Sciscent, B. Y., Eberly, H. W., Lorenz, F. J., Goldrich, D. Y., Goyal, N., & Goldenberg, D. (2026) · OTO Open · doi:10.1002/oto2.70188 · Cited by 2
“26,27 Longer ‐ term studies that assess the dose and duration of GLP ‐ 1RA use are needed to assess the risk of TC.”
Tilici, D.-M., Costinescu, R., Păun, D. L., Stegaru, D., Grecu, B. M., Costea, M., & Guja, C. (2026) · Epidemiologia · doi:10.3390/epidemiologia7020041
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“In rodents, GLP-1 receptor activation stimulates calcitonin secretion from thyroid C cells, and the skeletal phenotype observed in knockout models has therefore been partially attributed to reduced calcitonin-mediated inhibition of bone resorption [151, 152].”
Roach, K. A., Khazaee, M., Mohar, I., Boon, D., Cronin, B., & Gauthier, A. G. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106252
Metadata
- Authors
- Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H.
- Affiliations
- Department of Endocrinology (L.H.), Odense University Hospital, 5000 Odense, Denmark;
- Novo Nordisk Inc. (A.C.M.), Princeton, New Jersey 08540;
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S (M.Z., T.L.T.), 2880 Bagsværd, Denmark;
- Harvard University (US)
- ORCID
- Daniels, Gilbert H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-03-01
- Volume
- 96
- Issue
- 3
- Pages
- 853-860
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118710260
- Cited by
- 194
- References
- 25
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 14 · 2018: 7 · 2017: 7 · 2016: 10 · 2015: 26 · 2014: 19 · 2013: 28 · 2012: 29
- FWCI
- 23.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Funders
- Novo Nordisk
- Odense Universitetshospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- calcitonin, liraglutide, GLP-1 receptor agonists, type 2 diabetes, obesity, medullary thyroid carcinoma, long-term safety, rodent-to-human extrapolation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Adult, Calcitonin, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Receptors, Glucagon, Diabetes Complications, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.